Addex Therapeutics Ltd
NASDAQ: ADXN0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Capital Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Timothy Mark Dyer
- Employees
- 2
- Headquarters
- Geneva, Switzerland
- IPO year
- 2020
- Market cap
- $4.3M
- Website
- https://www.addextherapeutics.com
Loading ADXN…
Loading profile data…Frequently asked questions about ADXN
What does Addex Therapeutics Ltd (ADXN) do?
Addex Therapeutics Ltd, a biopharmaceutical firm in a developmental phase, operates out of Switzerland, focusing on the discovery, advancement, and commercialization of small-molecule drugs targeting central nervous system (CNS) disorders. Their core strategy involves identifying oral small-molecule allosteric modulators for G-protein coupled re...
Where does ADXN trade?
Addex Therapeutics Ltd (ADXN) trades on the NASDAQ Capital Market.
What sector is ADXN in?
Addex Therapeutics Ltd (ADXN) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Addex Therapeutics Ltd?
Timothy Mark Dyer is the chief executive officer of Addex Therapeutics Ltd (ADXN).
Where is Addex Therapeutics Ltd headquartered?
Addex Therapeutics Ltd is headquartered in Switzerland.
Does ADXN pay a dividend?
Addex Therapeutics Ltd (ADXN) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did ADXN go public?
Addex Therapeutics Ltd (ADXN) completed its initial public offering in 2020.
Is ADXN an ADR?
Yes — ADXN is an American Depositary Receipt; its underlying shares trade on a non-US exchange. Addex Therapeutics Ltd reporting and dividends follow the underlying issuer.